As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.
12 Analysts have issued a Monopar Therapeutics Inc forecast:
12 Analysts have issued a Monopar Therapeutics Inc forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -18 -18 |
120%
120%
|
Net Profit | -17 -17 |
118%
118%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Monopar Therapeutics, Inc. is a a clinical stage biopharmaceutical company, which engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Its product pipeline include Validive, Camsirubicin, and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr, and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
Head office | United States |
CEO | Chandler Robinson |
Employees | 15 |
Founded | 2014 |
Website | www.monopartx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.